For HIV-infected women, anti-müllerian hormone is associated with age of menopause onset, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.
Magnetic resonance imaging (MRI) shortly after birth might help determine which premature babies have sustained a brain injury that will affect their development, according to a study published online in Neurology.
Symbiomix announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Solosec (secnidazole oral granules) for the treatment of bacterial vaginosis (BV).
For infants with Prader-Willi syndrome (PWS), oxytocin (OXT) administration is associated with improvement in feeding and social skills, according to a study published online January 18 in Pediatrics.
Allergan and Gedeon Richter announced positive results from the second Phase 3 trial of ulipristal acetate, evaluating its efficacy and safety for the treatment of abnormal bleeding due to uterine fibroids in women.
Among women at risk for preeclampsia, antiplatelet agents reduce the risk of spontaneous preterm birth at less than 37 and less than 34 weeks of gestation, according to a meta-analysis published in the February issue of Obstetrics & Gynecology.
A short interpregnancy interval after termination of pregnancy is associated with increased risk of preterm birth in subsequent birth, according to a study published in the February issue of Obstetrics & Gynecology.
A quality improvement initiative can reduce the number of human milk administration errors in the neonatal intensive care unit, according to a study published online in Pediatrics.
In a recommendation statement published in the Jan. 10 issue of the Journal of the American Medical Association, the U.S. Preventive Services Task Force (USPSTF) reaffirms that folic acid supplements reduce the risk of neural tube defects.
AMAG pharmaceuticals and Palatin Technologies have entered into an agreement for the exclusive North American rights to develop and commercialize Rekynda (bremelanotide), an investigational drug to treat hypoactive sexual desire disorder (HSDD).
Use of acid suppressing agents during pregnancy may increase the risk of asthma in the offspring, according to a study published in The Journal of Allergy and Clinical Immunology.
The American Thyroid Association (ATA) has released new evidence-based recommendations to guide clinicians in diagnosing and managing thyroid disease during pregnancy and the postpartum period.
Pyridoxine-doxylamine (Diclectin), used to manage the nausea and vomiting associated with morning sickness, may not be as effective as once believed, according to a new analysis published online in PLOS One.
For high-risk women, letrozole is more effective than aspirin for decreasing the incidence of moderate and severe early-onset ovarian hyperstimulation syndrome, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.
Allergan and Medicines360 announced that the Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Liletta (levonorgestrel-releasing intrauterine system).
The highest amounts of spending were seen with these 10 conditions.
Data from a large, 1-year postmarketing safety study conducted in Europe found that lactation at the time of insertion of an IUD/IUS was associated with an increased risk of perforation.
Data from a randomized, double-blind clinical study found that the use of pritelivir led to a lower percentage of swabs with herpes simplex virus (HSV) detection over 28 days vs. valacyclovir. Full findings from the study are published in JAMA.
In a study published in Diabetes Care, researchers reported that the absolute risk of thromboembolism among women with type 1 or type 2 diabetes using hormonal contraceptives was low.
The presence of a non-Lactobacillus-dominated microbiota in a receptive endometrium is associated with poor reproductive outcomes for women undergoing in vitro fertilization (IVF).
Since 1999, the FDA has been evaluating the potential adverse effects of general anesthetics and sedatives on children's brain development.
Data from the Birth Defects Study found that influenza vaccination coverage rose during the 2012-13 and 2013-14 season from 35% to 41%, respectively.
The Centers for Disease Control and Prevention (CDC) issued the final report on the Winnable Battles program which highlights public health priorities with large-scale impact on health and strategies that may help to address them.
Women with immune-mediated diseases receiving anti-tumor necrosis factor (TNF)-alpha agents had significantly higher risks of preterm birth, spontaneous abortion, and low birth weight vs. the general population, a study published in the Journal of Autoimmunity found.
Concerns about gaining weight may impact contraception choices for women.
The FDA has approved Intrarosa (prasterone; Endoceutics) for the treatment of women experiencing moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
The labeling now includes a new Boxed Warning and a Patient Decision Checklist.
The Food and Drug Administration (FDA) has approved Bonjesta (doxylamine succinate and pyridoxine HCl extended-release tablets; Duchesnay), a fixed-dose combination drug product for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Allergan announced the availability of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, the first oral contraceptive in a softgel capsule for the prevention of pregnancy.
For women who are former hormone therapy users, risk of fracture is not increased after discontinuing therapy, according to a study published in the The Journal of Clinical Endocrinology & Metabolism.
Palatin has announced positive top-line results from the Phase 3 clinical trial of bremelanotide (a melanocortin 4 receptor agonist), an investigational treatment for hypoactive sexual desire disorder (HSDD).
BD announced that the Food and Drug Administration (FDA) has granted marketing clearance for BD MAX Vaginal Panel to detect the most common causes for vaginitis.
Pfizer announced a voluntary recall of one lot of Premarin (conjugated estrogens) 1.25mg tablets due to an incorrect expiration date applied to the bottle label.
A new study published online in the journal Contraception examines whether the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) is increased in women using non-oral combined hormonal contraceptives compared to women using combined oral contraceptives (COC).
AbbVie has announced positive results from two replicate Phase 3 clinical trials of Elagolix in premenopausal women with endometriosis.
The Food and Drug Administration (FDA) reports the discontinuation of Menest (esterified estrogens; Pfizer) 2.5mg tablets.
A new study of over 56,000 women found that those who purchased antidepressants at least twice during pregnancy had a 37% increased risk of speech and/or language disorder in their offspring compared to mothers who were not treated with antidepressants.
Par announced a voluntary recall of certain lots of Gildess, Gildess FE, and Gildess 24 FE products.
Progestin-containing intrauterine device (IUD) was deemed safe and acceptable as a long-acting contraceptive for women with epilepsy, a study published in Epilepsia has found.
As regulatory status of levonorgestrel emergency contraception has changed over the years, there has been increased confusion about how emergency contraception can be sold.
For women with type 1 diabetes, elevated fatty acid binding protein 4 (FABP4) in early pregnancy and in the second trimester is associated with subsequent preeclampsia, according to a study published online September 14 in Diabetes Care.
The FDA has accepted for review the New Drug Application (NDA) for Yuvvexy (17β-estradiol; TherapeuticsMD) for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA) in postmenopausal women.
Bayer announced that the Food and Drug Administration (FDA) has approved Kyleena (levonorgestrel-releasing intrauterine system) for the prevention of pregnancy for up to 5 years.
Data from a pilot randomized trial published in Nicotine & Tobacco Research showed that administering exogenous progesterone may potentially prevent postpartum smoking relapse.
The Food and Drug Administration (FDA) has issued a safety alert regarding the use of screening tests for ovarian cancer screening.
Ovarian cancer mortality is down dramatically in many parts of the world, and the use of oral contraceptives (OCs) may be a main reason why, according to a study published online in the Annals of Oncology.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SAGE-547 (Sage Therapeutics) for the treatment of postpartum depression (PPD).
Even though most new mothers in the United States begin breastfeeding their infants at birth, many stop sooner than recommended, according to the 2016 Breastfeeding Report Card from the U.S. Centers for Disease Control and Prevention.
Daily vaginal progesterone initiated at 16 weeks was a reasonable alternative to weekly 17-alpha-hydroxy-progesterone caproate (17-OHPC) for the prevention of spontaneous preterm birth in women with singleton gestations and prior spontaneous preterm birth, a systematic review in Obstetrics & Gynecology reported.
A review published in the Cochrane Database of Systematic Reviews generally found no association between higher body mass index (BMI) or weight and hormonal contraceptive efficacy.
Monogenic forms of diabetes can occur in preterm infants, according to a study published online in Pediatrics.
Use of antipsychotics (APs) in pregnancy does not appear to increase the risk for congenital malformations, according to a study published online in JAMA Psychiatry.
Antenatal administration of corticosteroids is not associated with a reduction in the incidence of respiratory distress syndrome (RDS) in preterm twins, according to research published in the September issue of Obstetrics & Gynecology.
Compared with current recommendations from professional societies, expanded carrier screening may increase the detection of carrier status for potentially serious genetic conditions, according to a study published in the Journal of the American Medical Association.
Onsite tests have high specificity for detecting asymptomatic bacteriuria among pregnant women, but sensitivity is lower, according to a review published in the September issue of Obstetrics & Gynecology.
Patients undergoing fertility treatment often suffer symptoms of depression or anxiety, but few get any formal help, according to research published in Fertility and Sterility.
An expert panel has proposed clinical guidelines for diagnosing fetal alcohol syndrome disorder (FASD), expanding upon the first guidelines from 2005 that helped distinguish the four subtypes of FASD.
Researchers from the National Institute of Environmental Health Sciences in Research reported that women risk having their vitamin D levels drop when they cease using contraceptives containing estrogen.
Consuming soy isoflavones may improve cardiovascular and metabolic health in women with polycystic ovary syndrome (PCOS), results from a new study in the Journal of Clinical Endocrinology & Metabolism has found.
Women with vaginal mesh with complications have a significantly increased proinflammatory response, according to a study published in the American Journal of Obstetrics & Gynecology.
Virtus has announced the launch of Prometrium (progesterone USP capsule).
The Centers for Disease Control and Prevention (CDC) released an update to the 2013 U.S. Selected Practice Recommendations for Contraceptive Use guideline after review of scientific data and expert consultation.
Obstetrician-gynecologists should counsel pregnant women about use of long-acting reversible contraception (LARC), such as implants and intrauterine devices (IUDs), immediately after they give birth, according to an American College of Obstetricians and Gynecologists (ACOG) Committee Opinion published in Obstetrics & Gynecology.
A bracelet that can track a woman's fertility has been launched today by the medical technology company Ava. In clinical trials the bracelet (which is worn only at night), detected an average of 5.3 fertile days per cycle with 89% accuracy.
Although evidence is limited, a new systematic review in Contraception indicates a greater risk of ovulation and breakthrough as well as reduced contraceptive efficacy when combined oral contraceptives (COCs) are co-administered with St. John's wort.
Inducing labor won't raise a pregnant woman's risk of having a child with autism, according to a study published online JAMA Pediatrics.
U.S. health officials on Monday updated their Zika virus guidelines, saying that pregnant women could contract Zika from a sex partner of either gender.
A new study has deemed that concern for clinically significant drug interactions between hormonal contraceptives (HC) and psychotropic drugs is low; however, the authors of the study did assert that more research is needed in this area.
Nanohealth announced the launch of the nanopause Bolero, a non-hormone product cleared by the Food and Drug Administration (FDA) to relieve symptoms of menopause such as hot flashes and night sweats.
Improvement in cognitive ability is not associated with estrogen therapy among women who use it after menopause, no matter when they start taking it, according to a study published online in Neurology.
Women who undergo in vitro fertilization (IVF) are not at increased risk of breast cancer, according to a study published in the issue of the Journal of the American Medical Association.
Decreasing caffeine intake may not help women prevent premenstrual syndrome (PMS), a team of researchers reported.
Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are associated with increased odds of bulimia nervosa (BN), but not with binge-eating disorder (BED), according to a study published in the July issue of the International Journal of Eating Disorders.
Continuation rates for intrauterine devices (IUDs) were generally higher vs. other contraceptive methods for women aged ≤25 years.
The diagnosis and management of polycystic ovary syndrome is discussed in a case vignette published online in The New England Journal of Medicine.
A patient-reported study of hormonal contraceptives has found a significantly varied effect on acne among commonly prescribed agents.
Breastfeeding premature infants appears to increase the likelihood that those infants will have healthier hearts in young adulthood, according to research published online in Pediatrics.
Among women with asymptomatic undiagnosed cervical infection or who are at high risk of sexually transmitted infections (STIs), intrauterine device (IUD) placement does not increase the risk of pelvic inflammatory disease (PID) compared with no IUD placement, a study published in Contraception has found.
New research suggests that the antiepileptic drug (AED) topiramate, when used in combination with other AEDs (excluding valproate) may enhance its propensity to cause fetal malformation.
Symbiomix announced positive results from the second pivotal Phase 3 trial of SYM-1219 (secnidazole) for the treatment of bacterial vaginosis (BV).
Prolactin receptor (PRLR) signaling plays a role in expansion of maternal β-cells during pregnancy, according to a study published online in Diabetes.
In the most definitive study to date, cigarette smoking during pregnancy was linked to a greater likelihood of schizophrenia in offspring. Those are the findings of a new long-term study which assessed maternal nicotine exposure (via cotinine levels) during pregnancy.
Researchers from Johns Hopkins Bloomberg School of Public Health reported that too much folate in a new mother's body may increase a child's risk of developing an autism spectrum disorder. Findings from the study will be presented at the 2016 International Meeting for Autism Research.
An updated Cochrane review found low or very low quality evidence.
Lupin Pharmaceuticals has announced the re-introduction of Methergine (methylergonovine maleate) Oral Tablets 0.2mg for the prevention and management of postpartum hemorrhage (PPH).
The Food and Drug Administration (FDA) is advising caution when prescribing oral fluconazole (Diflucan) in pregnancy after evaluating data from a Danish study that indicated a possible increased risk of miscarriage when used to treat yeast infections.
Hospira announced a voluntary recall of one lot of 50% Magnesium Sulfate Injection, 10g/20mL (0.5/gmL), 20mL single-dose vials.
A Cochrane review found no high quality evidence to support the efficacy of any dietary supplement for dysmenorrhea.
According to a study published in Neurology, babies born to pregnant women taking lamotrigine may not be at an increased risk of birth defects, such as a cleft lip, cleft palate or clubfoot.
The Society for Maternal-Fetal Medicine (SMFM) issued a statement on the use of antenatal corticosteroids during the late preterm birth period for women at risk of preterm birth.
Selective serotonin reuptake inhibitors (SSRIs) use during pregnancy and lactation can result in decreased bone density in mothers, increasing their risk of fractures later in life, a study presented at ENDO 2016 has found.
Polycystic ovary syndrome (PCOS) and excess weight have been independently linked with the onset of asthma, according to findings in a new study to be presented at the annual Endocrine Society meeting.
Radius Health announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for abaloparatide-subcutaneous (SC) 80mg, a once daily treatment for postmenopausal women with osteoporosis.
The Endocrine Society has issued a statement advising clinicians to avoid administering compounded hormone medications to treat menopausal symptoms, female sexual dysfunction, and other hormone conditions.
Expecting mothers should make sure they get enough vitamin D exposure during the second trimester to reduce the child's likelihood of developing asthma, according to new research by the University of Kansas published in the American Journal of Health Economics.
Researchers from Western Australia reported that seasonal influenza vaccinations may protect against stillbirth.
Drugs that were once considered safe for pregnant women with migraines may not be, according to researcher at Wake Forest Baptist Medical Center.
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mifeprex (mifepristone; Danco Laboratories) including modifications to the risk evaluation and mitigation strategy (REMS) assessment.
Researchers from the National Institutes of Health and Ohio State University report that the risk of miscarriage increases if couples consume over two caffeinated beverages a day in the weeks leading up to conception.